ALK-Abelló (Germany)

ALK-Abelló (Germany)

ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for ALK-Abelló (Germany), Germany, covering academic research published from 2001 to 2024. Read More.


Open Access Percentage

50%


Total
Publications

96


Total Open
Publications

48


Total
Citations

3.5K


Open Access
Percentage

50%


Total
Publications

96


Total Open
Publications

48


Total
Citations

3.5K

Wikipedia

Website

download

Breakdown

27% 13% 6% 54%

Publisher Open

27%

Both

13%

Other Platform Open

6%

Closed

54%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0123456789Total Publications
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

33%OA Journal

OA Journal 33%

12

Hybrid 11%

4

No Guarantees 56%

20

Other Platform Open

Domain 67%

12

Institution 39%

7

Other Internet 6%

1

Preprint 0%

0

Public 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
12
University of Turin - Institutional Research Information System University of Turin
Institution
1
Universidad Politécnica de Madrid - Archivo Digital UPM
Institution
1
Universidad del Pais Vasco - Communities in ADDI
Institution
1
Site cant be reached
Institution
1
Scientific periodicals of Ukraine
Institution
1
Leibniz Universität Hannover - Institutional Repository of Leibniz Universität Hannover
Institution
1
Konstfack University of Arts, Crafts, and Design - Publications
Institution
1
Europe PMC
Domain
1
Econstor - Econstor
Other Internet
1
1 / 2

Data updated 18 August 2025

Share

Share

Share